Skip to Content
  • MyChart

    Log in to our secure, personalized website to manage your care (formerly myMDAnderson).

  • Request an Appointment

    If you are ready to make an appointment, select a button on the right. If you have questions about UT MD Anderson’s appointment process, our information page may be the best place to start.

    Appointment Information
    New Patients Current Patients Referring Physicians
  • Every Breakthrough
    Begins With You

    Gifts to UT MD Anderson’s historic philanthropic campaign help accelerate discovery, transform lives and bring hope to more patients than ever before.

    Learn more about Only Possible Here
    Donate Today only-possible-here-logo
The University of Texas MD Anderson Cancer Center
  • Clinical Trials
  • Locations
  • Careers
  • Contact Us
  • Our Doctors
    • Español
    • عربى
    • 中文
    • Türkçe
Clear
close
      MyChart
      Donate Today
      • Clinical Trials
      • Locations
      • Careers
      • Contact Us
        • Español
        • عربى
        • 中文
        • Türkçe
      • Request an Appointment
      • New Patients
      • Current Patients
      • Referring Physicians
      • Patients & Family
          • Becoming Our Patient Home
          • Why UT MD Anderson
          • Planning for Care
          • Getting to UT MD Anderson
          • While You're Here
          • International Center
          • Services and Amenities
          • Insurance & Billing
          • Second Opinion Appointments
          • Diagnosis & Treatment Home
          • Cancer Types
          • A New Diagnosis
          • Treatment Options
          • Care Centers & Clinics
          • Emotional & Physical Effects
          • Patient Support
          • Clinical Trials
          • Supporting a Loved One Home
          • Caregiver Roles & Challenges
          • Children and Teens
          • Taking Care of Yourself
          • Helping a UT MD Anderson Patient
          • Dealing with Loss
          • Life After Cancer Home
          • Follow-up Care After Cancer Treatment
          • Long-Term Effects of Cancer
          • Social & Emotional Impacts of Cancer
          • Legal & Financial Impacts of Cancer
          • Survivorship Week
        • Request an Appointment Current Patients

          Find information and resources for current and returning patients.

          Clinical Trials

          Learn about clinical trials at UT MD Anderson and search our database for open studies.

      • Prevention & Screening
          • Manage Your Risk Home
          • Tobacco Control
          • Diet
          • Body Weight
          • Physical Activity
          • Skin Safety
          • HPV
          • Hepatitis
          • Alcohol
          • Family History Home
          • Genetic Testing
          • Hereditary Cancer Syndromes
          • Genetic Counseling and Testing FAQs
          • Cancer Screenings Home
          • Mammograms & Breast Cancer Screening
          • Cervical Cancer Screening
          • Colorectal Cancer Screening
          • Endometrial Cancer Screening
          • Liver Cancer Screening
          • Lung Cancer Screening
          • Mobile Mammography
          • Ovarian Cancer Screening
          • Prostate Cancer Screening
          • Skin Cancer Screening
          • Women's Cancer Screening
          • Men's Cancer Screening
        • Cancer Prevention Center 

          The Lyda Hill Cancer Prevention Center provides cancer risk assessment, screening and diagnostic services.

      • Donors & Volunteers
          • Donate Home
          • Raise Money
          • Honor Loved Ones
          • Create Your Legacy
          • Endowments
          • Caring Fund
          • Matching Gifts
          • Foundation and Corporation Relations
          • Volunteer Home
          • Why Volunteer
          • On-Site Volunteers
          • Volunteer Endowment
          • Patient Experience
          • Teen Volunteer Leadership Program
          • Children's Cancer Hospital Councils
          • Other Ways to Help Home
          • Give Blood
          • Shop UT MD Anderson
          • Children's Art Project
          • Donate Goods or Services
          • Attend Events
          • Cord Blood Bank
          • Corporate Alliances Home
          • Current Alliances
        • Join the Campaign to End Cancer 

          Help us celebrate and fuel the groundbreaking innovations and transformative advancements that define UT MD Anderson.

      • For Physicians
          • Refer a Patient Home
          • Health Care Provider Resource Center
          • Referring Provider Team
          • Insurance Information
          • International Referrals
          • myMDAnderson for Physicians
          • Second Opinion Pathology
          • Clinical Trials Home
          • Clinical Tools & Resources Home
          • Clinical Calculators
          • Clinical Practice Algorithms
        • myMDAnderson for Physicians 

          Our personalized portal helps you refer your patients and communicate with their UT MD Anderson care team.

      • Research
          • Departments, Labs and Institutes Home
          • Departments and Divisions
          • Labs
          • Research Centers and Programs
          • Institutes
          • Specialized Programs of Research Excellence (SPORE) Grants
          • Research Areas Home
          • Basic Science
          • Translational Research
          • Clinical Research
          • Prevention & Personalized Risk Assessment
          • Research Resources Home
          • Excellence in Science
          • Core Facilities and Services
          • Conferences & Seminars
          • Why Research at UT MD Anderson
          • STRIDE
          • NCI-Designated Cancer Center
          • Data Resources
        • Clinical Trials 

          As part of our mission to eliminate cancer, UT MD Anderson researchers conduct hundreds of clinical trials to test new treatments for both common and rare cancers.

      • Education & Training
          • Degree-Granting Schools Home
          • School of Health Professions
          • MD Anderson UTHealth Houston Graduate School
          • Research Training Home
          • Early Career Pathway Programs
          • Predoctoral Training
          • Postdoctoral Training
          • Mentored Faculty Programs
          • Career Development
          • Clinical Training Home
          • Graduate Medical Education
          • Clinical Education for Non-Physicians
          • Nursing Education & Training
          • Continuing Education & Review Courses
          • Simulation Center
          • Continuing Education & Professional Development Home
          • Continuing Professional Education/Conferences
          • Administrative Internships & Fellowships
          • Cancer Survivorship Professional Education
          • Leadership Institute
          • Patient Home Visits
          • Education Resources Home
          • Alumni Relations
          • Education Design Services
          • Awards & Recognitions
          • Academic Mentoring Council
          • Why UT MD Anderson & Houston
          • Outreach Programs Home
          • Project ECHO
          • Observer Programs
          • Comparative Effectiveness Training (CERTaIN)
          • Faculty Speakers Bureau
        • Apply to SHP

          Choose from 12 allied health programs at School of Health Professions.

          Research Trainees

          View open postdoctoral and other research trainee positions.

          GME Fellowships

          Learn about our graduate medical education residency and fellowship opportunities.

      Melissa P Mitchell Image

      Melissa P Mitchell, MD, PhD

      Department of Breast Radiation Oncology, Division of Radiation Oncology

      About Melissa P Mitchell

      Dr. Mitchell treats all types of breast cancer and is interested in developing a tailored radiation approach for each patient based on stage and tumor biology. With an interest in treatment de-escalation, Dr. Mitchell has performed funded research to assess whether radiosensitivity could be utilized for clinical decision making for adjuvant radiation in patients with ductal carcinoma in situ.  Dr. Mitchell has developed a clinical trial to eliminate radiation as a component of treatment for early-stage patients with her-2 positive breast cancer who have an excellent response to treatment.  She has also served as the principal investigator on a clinical trial of hypofractionation in locally advanced breast cancer, treating patients with radiation therapy at a reduced total dose and with shorter treatment time, in the hopes of reducing treatment-related toxicity, such as lymphedema.  With a background in pharmacology, she also has an interest in combining new pharmaceutical agents with radiation in patients with more aggressive tumors that show evidence of radiation resistance.  Furthermore, she is interested in patient quality of life and is working on developing a new validated tool to assess patient-reported toxicity in patients undergoing breast radiotherapy.
      Read More

      Present Title & Affiliation

      Primary Appointment

      Associate Professor, Department of Breast Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX

      Dual/Joint/Adjunct Appointment

      Associate Professor, Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX

      Education & Training

      Degree-Granting Education

      2006University of Colorado School of Medicine, Denver, Colorado, US, MD
      2004University of Colorado School of Medicine, Denver, Colorado, US, Pharmacology, Ph.D
      1999Northwestern University, Evanston, Illinois, US, Dual degree in Biology and Integrated Science Program, BA

      Postgraduate Training

      2011-2012Clinical Fellowship, Radiation Oncology, M.D. Anderson Cancer Center, Houston
      2007-2011Clinical Residency, Radiation Oncology, University of Kansas, Kansas City, Kansas
      2006-2007Clinical Internship, Internal Medicine, University of Kansas, Kansas City, Kansas

      Licenses & Certifications

      2022Georgia Composite Medical Board
      2022Oklahoma State Board of Medical Licensure
      2022Tennessee Board of Medical Examiners
      2022Arizona Board of Medical Examiners
      2022Louisiana State Board of Medical Examiners
      2022Alabama Board of Medical Examiners
      2022Mississippi State Board of Medical Licensure
      2021Florida Board of Medicine
      2019Texas Medical Board
      2012American Board of Radiology
      nullBasic Life Support
      nullDEA

      Experience & Service

      Faculty Academic Appointments

      Assistant Professor, Radiation Oncology, The University of Kansas, Kansas City, KS, 2012 - 2019

      Administrative Appointments/Responsibilities

      Operations, Department of Breast Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2023 - Present

      Associate Medical Director, Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2020 - Present

      Radiation Oncology Compensation Committee, Radiation Oncology, The University of Kansas Cancer Center, Kansas City, KS, 2018 - 2019

      Physician lead for Clinical Operations, Radiation Oncology, The University of Kansas Cancer Center, Kansas City, KS, 2016 - 2019

      Executive Committee for Radiation Oncology, Radiation Oncology, The University of Kansas Cancer Center, Kansas City, KS, 2015 - 2019

      Other Professional Positions

      Volunteer Faculty, UH College of Medicine, Houston, TX, 2023 - 2019

      Consultant, Hylapharm, Lawrence, KS, 2018 - 2019

      Program Evaluation Committee Chair, The University of Kansas Cancer Center, Kansas City, KS, 2017 - 2019

      Physician Recruitment Committee, The University of Kansas Cancer Center, Kansas City, KS, 2015 - 2016

      Research Committee Leader, The University of Kansas Cancer Center, Kansas City, KS, 2015 - 2016

      Cancer Service Line member/Steering Committee, The University of Kansas Cancer Center, Kansas City, KS, 2015 - 2019

      Program Evaluation Committee Member, The University of Kansas Cancer Center, Kansas City, KS, 2013 - 2019

      Intramural Institutional Committee Activities

      Board Member, Technology Assessment Committee (TAC), The University of Texas MD Anderson Cancer Center, 2025 - Present

      Representative, MD Anderson Clinical Operations, The University of Texas MD Anderson Cancer Center, 2025 - Present

      Extramural Institutional Committee Activities

      Member, Comparative Plan Request Automation Committee, The University of Texas MD Anderson Cancer Center, 2023 - Present

      Department Representative, Advanced Breast Cancer, The University of Texas MD Anderson Cancer Center, 2023 - Present

      Member, Invasive Lobular working group, The University of Texas MD Anderson Cancer Center, 2023 - Present

      Member, X-met Pillar Working Group, The University of Texas MD Anderson Cancer Center, 2023 - 2024

      Member, Breast Planning Directive and Contour Standardization Committee, The University of Texas MD Anderson Cancer Center, 2022 - Present

      Member, Particle Therapy Task Clinical Working Group, The University of Texas MD Anderson Cancer Center, 2022 - Present

      Faculty Informal Interviews, Residency Selection Committee, The University of Texas MD Anderson Cancer Center, 2021 - 2023

      Department of Radiation Oncology Lead, Joint Plastic Surgery | Breast Surgery | Radiation Oncology Conference Committee, The University of Texas MD Anderson Cancer Center, 2020 - Present

      Member, Breast One RO Standardization Committee, The University of Texas MD Anderson Cancer Center, 2020 - 2021

      Radiation Oncology Lead, Institutional Breast Algorithms Committee, The University of Texas MD Anderson Cancer Center, 2020 - Present

      Member, Bone Metastasis Committee, The University of Texas MD Anderson Cancer Center, 2020 - Present

      Member, Medical Practice Committee, The University of Texas MD Anderson Cancer Center, 2019 - Present

      Member, Diversity Recruitment, The University of Kansas Hospital, 2017 - 2018

      Member, Hospital Cohort Nominating Committee, University of Kansas, 2017

      Radiation Oncology Lead, National Accreditation of Programs in Breast Cancer Committee, The University of Kansas Cancer Center, 2016 - 2019

      Second Line Representative, Committee on Cancer, The University of Kansas Cancer Center, 2015 - 2019

      Member, Physician EMR Executive Committee (eIPAC), The University of Kansas Hospital, 2015 - 2016

      Committee Leader, Department of Radiation Oncology, Breast Cancer Radiation Oncology Guidelines, The University of Kansas Cancer Center, 2015 - 2016

      Co-Chair, Breast Disease Working Group, The University of Kansas Cancer Center, 2013 - 2019

      Breast Cancer Lead, Department of Radiation Oncology, Mock Oral Examination Workshop, The University of Kansas Cancer Center, 2013 - 2019

      Editorial Activities

      Associate Editor Breast Track, Practical Radiation Oncology, 2018 - Present

      Honors & Awards

      2022Excellence in Safety Award, MD Anderson Cancer Center
      2019Educator of the Year, ARRO
      2019Featured article in the Springer column, ASCO
      2018Nomination for Phase I Committee, KUMC School of Medicine
      2018Top Doctors in Kansas City, Ingram’s Magazine
      2017SWOG Travel Grant, SWOG
      2014Nomination for Gold Humanism Honor Society, Gold Humanism Honor Society
      2009Second place poster award in biology, ASTRO
      2002 - 2006Individual NRSA fellowship grant, NIEHS
      1999Graduate Merit Training Grant
      1999IBM Grant for Women in Research, Women in Research
      1998Erwin Macy Scholarship

      Professional Memberships

      American Radium Society (ACR)

      2024 - Present

      I-SPY2: De-Escalating RT and Local Therapy Working Group

      2023 - 2024

      American College of Radiology

      2021 - Present

      Alliance Oncology

      2018 - Present

      NRG Oncology

      2018 - Present

      American Brachytherapy Society

      2013 - 2015

      American Society of Radiation Oncology

      2007 - Present

      Selected Presentations & Talks

      Local Presentations

      1. 2025. Postmastectomy Radiation Therapy: A ASTRO/ASCO/SSCO Clinical Practice Guideline. Invited. Podcast. Houston, Texas, US.
      2. 2025. Updates on Advanced Breast Cancer: Local Management and Other New Perspectives. Invited. Houston, Texas, US.
      3. 2024. Multidisciplinary approaches to SLN and ALND omission based on the SOUND, SENOMAC AND AMAROS trials. Panelist. Breast Cancer Clinical and Translational Research (BCCTR) Conference. Houston, Texas, US.
      4. 2024. Timing Matters: Integrating Breast Reconstruction and Adjuvant Therapies. Houston, Texas, US.
      5. 2024. Radiation Oncology Perspective of ILC Treatment. Invited. Houston, Texas, US.
      6. 2023. Axillary Management with Mastectomy in cN0 patients. Invited. Radiation Oncology Perspective BCCTR. Houston, Texas, US.
      7. 2023. SABCS Review. Invited. Houston, Texas, US.
      8. 2022. Treatment De-escalation: What does the data tell us?. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
      9. 2021. Practical Radiation Oncology, "Fast" Breast Irradiation – Opportunities and Unknowns of Whole and Partial Treatment Options. Invited. Podcast. Houston, Texas, US.

      National Presentations

      1. 2025. Debate – Cons of Protons for Breast Cancer. Invited. PTCOG-NA 11th Annual Meeting. Shreveport, Louisiana, US.
      2. 2025. Eliminating Radiotherapy in Exceptional Responders. Invited. Rush Cancer Symposium. Chicago, Illinois, US.
      3. 2025. Biologically informed radiotherapy for breast cancer. ARS 107th Annual Meeting. Seattle, Washington, US.
      4. 2023. Automated Planning and Contouring. Conference. DAVA Oncology, US.
      5. 2023. Omission of RT in exceptional responders. Conference. DAVA Oncology, HI, US.
      6. 2023. Use of genomic assays to guide RT. Conference. DAVA Oncology, US.
      7. 2022. The role of advanced radiation technology in reducing toxicity. Invited. SABCS. San Antonio, TX, US.
      8. 2021. Genomic Profiling and Radiosensitivity. Conference. MJH Life Sciences. Dallas, US.
      9. 2021. Genomic Profiling and Radiosensitivity. Conference. MJH life sciences. Orlando, US.
      10. 2019. Reconstruction: A Multidisciplinary Approach. Invited. Plastic Surgery the Meeting. San Diego, CA, US.

      International Presentations

      1. 2025. Role of Radiotherapy in Stage IV Breast Cancer. Invited. Indonesia, US.
      2. 2025. Can Radiation Replace Axillary Dissection in Patients with Persistent Node Positive Disease after Neoadjuvant Chemotherapy. Invited. Oaxaca, MX.
      3. 2025. Debate – Pros of Radiotherapy for DCIS. Invited. Oaxaca, MX.
      4. 2025. Radiation Decisions in the Setting of Sentinel Node Biopsy Omission. Invited. Oaxaca, MX.
      5. 2024. Treatment Strategy for Axillary Lymph Node of Breast Cancer (Surgery or Radiotherapy?). Invited. CCMC Symposium 2024, CN.
      6. 2024. Elimination of Radiotherapy After Neoadjuvant Systemic Treatments. Invited, MX.
      7. 2024. Elimination of breast surgery after systemic treatment. Invited. National Congress, MX.
      8. 2024. Elimination of breast surgery after systemic treatment. Invited. CCCM Symposium 2024, CN.
      9. 2024. Radiation Oncology: Hypofractionation vs conventional radiotherapy after breast cancer surgery. Invited, ID.
      10. 2024. Evidence Supporting the Use of Particle Therapy to Reduce Cardiac Exposure in Breast Malignancies. Invited. 62nd Annual PTCOG Conference & 4th PTCOG-AO Meeting, SG.
      11. 2024. De-escalation of Breast Radiation in the Era of Improved Systemic Therapy and Genomic Profiling. Invited. IOSC 2024, AE.
      12. 2024. IMPT for breast cancer role in dermatitis reduction and integration of DIBH. Invited. Guangzhou, CN.
      13. 2023. Use of Protons for Breast Radiotherapy. Conference. MDACC/CCM Joint Academic Conference, US.
      Read More
      Less

      Grant & Contract Support

      Date: 2026 - 2030
      Title:Novel, personalized, response-guided paradigm for invasive breast cancer treatment without breast surgery or without radiation
      Funding Source:CPRIT
      Role:PI
      Date: 2025 - 2028
      Title:AI-based end-to-end radiotherapy planning for breast cancer: Prospective evaluation and risk reduction
      Funding Source:Cancer Prevention Research Institute of Texas
      Role:Co-I
      ID:RP260167
      Date: 2023 - 2024
      Title:Artidis Alliance Project 2016-0046
      Funding Source:Artidis
      Role:Subaward Investigator
      ID:AWD00007031, RCTS#00061840
      Date: 2021
      Title:Radioresistance of Ductal Carcinoma in Situ Versus Invasive Breast Carcinoma, NCI Clinical and Translational Exploratory/Developmental Studies
      Funding Source:NIH/NCI
      Role:Co-PI
      ID:PAR-20-292
      Date: 2019 - 2020
      Title:The Grand Challenge: When is Cancer Not Cancer
      Funding Source:UK PRECISION
      Role:Co-I
      Date: 2019 - 2019
      Title:Breast Cancer Fatigue and Mitochondrial Gene Expression in Black and White Women
      Funding Source:KUCC Pilot Project
      Role:Co-I
      Date: 2016 - 2018
      Title:Qigong Intervention for Breast Cancer Survivors with Complaints of Decreased Cognitive Function
      Funding Source:Oncology Nursing Society Foundation Nursing
      Role:Co-I
      Date: 2013 - 2014
      Title:Development of a Radiosensitivity Assay for DCIS
      Funding Source:KU Cancer Center
      Role:PI
      Date: 2002 - 2006
      Title:F30ES012347 NRSA fellowship grant awarded from the NIEHS, Signaling Mechanisms of Ozonized Pulmonary Surfactant
      Funding Source:NIH/NIEHS
      Role:PI
      Title:Breast Cancer Research Program Breakthrough Award Level 1
      Funding Source:Department of Defense (DOD)
      Role:PI
      Title:Fatigue, quality of life, and leukocyte transcriptomes in black and white breast cancer patients
      Funding Source:NIH/NCI
      Role:Co-I
      Title:Development of a Radiosensitivity Assay for Clinical Use in DCIS
      Funding Source:American Cancer Society (ACS)
      Role:PI
      Title:Psychoneurological Symptom Cluster, Lifetime Stress Exposure and Radiation Treated Breast Cancer
      Funding Source:NIH/NCI
      Role:Co-I
      Title:Measurement of Cognitive Effort for Breast Cancer Survivors
      Funding Source:NIH/NCI
      Role:Co-I

      Selected Publications

      Peer-Reviewed Articles

      1. Mauricio R, Deswal A, Ruddy KJ, Akhter N, Chen MH, Ebong IA, Aggarwal NR, Harrington CM, Barcenas CH, Mitchell MP, Cho L, Nohria A. Cardiovascular Health Across the Life Course for Individuals With Breast Cancer. JAMA Cardiology, 2026. e-Pub 2026. PMID: 42525430.
      2. Genevieve A Fasano MD, Jason Mouabbi MD, Helen M Johnson MD, Lin PhD HY, Kerollos Nashat Wanis MD, PhD, Susie X Sun MD, Anthony Lucci MD, Vicente Valero MD, Melissa Mitchell MD, PhD YS, Kelly K Hunt MD, Henry Kuerer MD, PhD. Clinical Impact and Outcomes of Neoadjuvant Systemic Therapy for Invasive Lobular Carcinoma. Annals of Surgical Oncology, 2026. e-Pub 2026.
      3. Mitchell, MP, Adesoye, T, Shaitelman, SF, Barcenas, CH, Hwang, RF. Lymph Node Management of Patients With Breast Cancer in the Era of Therapy De-escalation. Practical radiation oncology 16(4):376-383, 2026. e-Pub 2026. PMID: 41758096.
      4. Shaitelman, SF, Krishnamurthy, S, Rauch, GM, Lin, Y, Shen, Y, Valero, V, Johnson, HM, Muruganandham, M, Smith, B, Hoffman, K, Lee, B, Shinn, EH, Symmans, WF, Woodward, W, Mitchell, MP, Goodman, C, Buzdar, AU, Singh, P, Tamirisa, N, Kuerer, HM. Definitive, stereotactic ablative radiotherapy and endocrine therapy without surgery for select low-risk breast cancers. Radiotherapy and Oncology 220, 2026. e-Pub 2026. PMID: 42142534.
      5. Mitchell MP. Customized radiation post neoadjuvant chemotherapy in breast cancer. The Lancet Oncology, 2026. e-Pub 2026. PMID: 42372738.
      6. Shaitelman SF, Krishnamurthy S, Rauch GM, Lin H, Shen Y, Valero V, Johnson HM, Muruganandham M, Smith BD, Hoffman KE, Lee BM, Shinn E, Symmans W, Woodward WA, Mitchell MP, Goodman CR, Buzdar A, Singh P, Tamirisa N, Kuerer H. Definitive, stereotactic ablative radiotherapy and endocrine therapy without surgery for select low-risk breast cancers: A prospective, phase II trial. Radiotherapy and Oncology, 2026. e-Pub 2026.
      7. Smith GL, Wu C, Joyner M, Schlembach PJ, Bloom ES, Reed VK, Graybill J, Anderson C, Lin R, Dragun A, Ceilley E, Garg AK, Freeman A, Diavolitsis V, Mayo L, Bowers J, Neisler K, Reddy J, Ahlawat S, Khan M, Mitchell M, Arzu I, Tsuji SY, DeHaan M, Jain S, Greenwalt J, Rehman S, Zaki M, Wei SJ, Chavez-MacGregor M, Giordano SH, Shen Y, Kaiser KW, Smith BD, O’Steen L, Sangave A, Anderson TM, Gopal R, Weed D, Fugazzi J, Nicholas S, Goodman C, Chun SG, Grade E, Nabhani T, Nead KT, Wiederhold L, Albert J, Kudithipudi V, Michaud A, Anakwenze CP, Shaitelman SF, Hoffman KE, Clayton R. Financial Toxicity of Shorter Versus Longer Partial Breast Irradiation: A Randomized Clinical Trial. International Journal of Radiation Oncology, Biology, Physics, 2026. e-Pub 2026.
      8. Braunstein LZ, Mitchell MP, Khan AJ, Sikov WM, Mamounas EP, Julian TB, Wolmark N. Headwinds in Breast Cancer Research: The Case for Pragmatic Radiotherapy De-escalation Studies. Journal of Clinical Oncology. e-Pub 2026.
      9. Lattimore CM, Wanis KN, Kuerer HM, Hunt KK, Giordano SH, Mitchell MP, Shaitelman SF, Tamirisa N, Shen Y, Dong W, Johnson HM. Is mastectomy necessary in patients with occult breast cancer and advanced (N2/N3) nodal disease?. Annals of Surgical Oncology. e-Pub 2026.
      10. Azhar, M, Soto, F, Su, A, Gonzalez, NV, Medina, KB, Madrigal, AL, Duran, CC, Reyna, CR, Chan, C, Shroff, G, Bassett Jr, R, Pasyar, S, Zhang, D, Shannon, VR, Altan, M, Mitchell, MP, Meric-Bernstam, F, Mouabbi, JA, Murthy, RK, Faiz, S, Bashoura, L, Lim, B, Sheshadri, A. Incidence and risk factors for pneumonitis due to trastuzumab Deruxtecan in metastatic breast cancer. Breast Cancer Research 27(1), 2025. e-Pub 2025. PMID: 41194091.
      11. Yi, M, Chavez Mac Gregor, M, Smith, B, Mitchell, MP, Caudle, AS, DeSnyder, SM, Kuerer, HM, Hunt, KK. Comparing Survival Differences between Patients Undergoing Breast-Conserving Therapy Versus Total Mastectomy as a First Treatment for Early Stage Breast Cancer. Annals of surgical oncology 32(13):9757-9766, 2025. e-Pub 2025. PMID: 40789993.
      12. Clemens, MW, Mitchell, MP, Christensen, JM, Olenczak, JB, Shay, PL, Hanwright, P, Ha, A, Kapur, SK, Melancon, AD, Shuck, JW. Magnetic Resonance Imaging-Conditional Tissue Expanders in Breast Reconstruction. Plastic and Reconstructive Surgery 156(2):225-233, 2025. e-Pub 2025. PMID: 39946673.
      13. Wanis, K, Mitchell, MP, Giordano, SH, Litton, J, Shaitelman, SF, Tamirisa, N, Bedrosian, I, Dong, W, Shen, Y, Hunt, KK, Singh, P, Sun, SX, Caudle, AS, Kuerer, HM, Meric-Bernstam, F, Hwang, RF, Adesoye, T. Implications of omitting sentinel lymph node biopsy on adjuvant decision making for patients with small breast cancers. Cancer 131(11), 2025. e-Pub 2025. PMID: 40433858.
      14. Jacomina, LE, Swanson, DM, Mitchell, MP, Woodward, W, Smith, B, Hoffman, K, Goodman, C, Garber, HR, Sun, SX, Yap, TA, Meric-Bernstam, F, Arzu, I, Bloom, ES, Schlembach, PJ, Strom, EA, Stauder, MC, Shaitelman, SF. Outcomes After Palliative Radiation Therapy in Patients With Symptomatic Locoregionally Advanced Breast Cancer. International Journal of Radiation Oncology Biology Physics 122(2):278-291, 2025. e-Pub 2025. PMID: 39549757.
      15. Kuerer, HM, Valero, V, Smith, BD, Krishnamurthy, S, Diego, EJ, Johnson, HM, Lin, Y, Shen, Y, Lucci, A, Shaitelman, SF, Mitchell, MP, Boughey, JC, White, RL, Hunt, KK, Yang, WT, Rauch, GM, Moseley, T, Leung, J, Huang, ML, Candelaria, RP, Adrada, BE, Arribas, E, van la Parra, RF, Ramirez, DL, Teshome, M, Hwang, RF, Miggins, MV, Piotrowski, MJ, Correa Refinetti, AP, Ehlers II, RA, Mouabbi, JA, Colen, JS, Loveland-Jones, C, Lesnikowski, BA, Samiian, L, Chong, C, Black, DM, Desyder, SM, Sun, SX, Nguyen, TM. Selective Elimination of Breast Surgery for Invasive Breast Cancer A Nonrandomized Clinical Trial. JAMA Oncology 11(5):529-534, 2025. e-Pub 2025. PMID: 40152443.
      16. Reddy, JP, Sherry, AD, Fellman, B, Liu, S, Bathala, TK, Haymaker, CL, Cohen, L, Smith, B, Ramirez, DL, Shaitelman, SF, Chun, SG, Medina-Rosales, M, Teshome, M, Brewster, A, Barcenas, CH, Reuben, A, Ghia, AJ, Ludmir, EB, Weed, D, Shah, SJ, Mitchell, MP, Woodward, W, Gomez, D, Tang, C. Adding Metastasis-Directed Therapy to Standard-of-Care Systemic Therapy for Oligometastatic Breast Cancer (EXTEND). International Journal of Radiation Oncology Biology Physics 121(4):885-893, 2025. e-Pub 2025. PMID: 39486645.
      17. Baroudi, H, Che Fru, L, Schofield, D, Roniger, DL, Nguyen, C, Hancock, D, Chung, CV, Beadle, BM, Gifford, KA, Netherton, T, Niedzielski, JS, Melancon, AD, Muruganandham, M, Khan, M, Shaitelman, SF, Shete, S, Murina, P, Venencia, D, Thengumpallil, S, Vrieling, C, Zhang, J, Mitchell, MP, Court, LE. An automated treatment planning portfolio for whole breast radiotherapy. Medical physics 52(3):1779-1788, 2025. e-Pub 2025. PMID: 39699058.
      18. Braunstein, L, Mitchell, MP, Bandos, H, Sikov, W, Khan, AJ, Chen, PY, Ganz, PA, Jagsi, R, White, J, Cecchini, RS, Kang, H, Puhalla, S, Bolton, KL, Connolly, E, Stringer-Reasor, E, Gergelis, KR, Julian, TB, Mamounas, EP, Wolmark, N. A phase III randomized trial of radiotherapy optimization for low-risk HER2-positive breast cancer (HERO). Journal of Clinical Oncology 43(16), 2025. e-Pub 2025. PMID: 40574381.
      19. Braunstein, L, Mitchell, MP, Bandos, H, Sikov, W, Khan, AJ, Chen, PY, Ganz, PA, Jagsi, R, White, J, Cecchini, RS, Kang, H, Puhalla, S, Bolton, KL, Connolly, E, Stringer-Reasor, E, Gergelis, KR, Julian, TB, Mamounas, EP, Wolmark, N. NRG-BR008/HERO study. Future Oncology 21(16):2017-2025, 2025. e-Pub 2025. PMID: 40574381.
      20. Mitchell, MP, Shaitelman, SF, Smith, BD, Krishnamurthy, S, Valero, V, Rauch, GM, Shen, Y, Lin, Y, Kuerer, HM. Feasibility of breast conserving surgery alone in HER2-positive exceptional responders to neoadjuvant systemic therapy. European Journal of Surgical Oncology 50(12), 2024. e-Pub 2024. PMID: 39243728.
      21. Camacho L, Chu CK, Mitchell MP, Nguyen T, Correa A, Mericli AF. Oncoplastic Reconstruction in the Setting of Prior Cosmetic Augmentation. Plast Reconstr Surg 154(5):919-928, 2024. e-Pub 2024. PMID: 38376232.
      22. Weng, JK, Virk, R, Kaiser, KW, Hoffman, K, Goodman, C, Mitchell, MP, Shaitelman, SF, Schlembach, PJ, Reed, VK, Wu, C, Xiao, L, Smith, GL, Smith, BD. Automated, Real-Time Integration of Biometric Data From Wearable Devices With Electronic Medical Records. JCO Clinical Cancer Informatics 8, 2024. e-Pub 2024. PMID: 39348612.
      23. Weiss A, Colugnati F, Mitchell M, Li Y, Marin C, Gergelis KR, O'Sullivan CC, Boughey JC. ASO Visual Abstract: Contemporary Axillary Surgical Management in Patients with Pathologically Node-Positive Disease After Neoadjuvant Chemotherapy: A Survey of Members of the American Society of Breast Surgeons. Ann Surg Oncol. e-Pub 2024. PMID: 39117930.
      24. Kim M, Maldonado JA, Pandey P, El Alam MB, Kouzy R, Christopherson K, Minsky BD, Nugyen QN, Grosshans D, Lin LL, Mitchell MP, Klopp AH, Lee PP, Bird J, Satcher R, Lewis VO, Lin PP, Tang C, Koong AC, Moon B, Colbert LE. Single-fraction radiation retreatment for bone metastases: role of a rapid access clinic. BMJ Support Palliat Care 14(e2), 2024. e-Pub 2024. PMID: 38843933.
      25. Schaverien MV, Singh P, Smith BD, Qiao W, Akay CL, Bloom ES, Chavez-MacGregor M, Chu CK, Clemens MW, Colen JS, Ehlers RA, Hwang RF, Joyner MM, Largo RD, Mericli AF, Mitchell MP, Shuck JW, Tamirisa N, Tripathy D, Villa MT, Woodward WA, Zacharia R, Kuerer HM, Hoffman KE. Premastectomy Radiotherapy and Immediate Breast Reconstruction: A Randomized Clinical Trial. JAMA Netw Open 7(4):e245217, 2024. e-Pub 2024. PMID: 38578640.
      26. Morse RT, Moreno M, Butterworth JA, Mitchell MP. Interplay of Oncoplastic Reconstruction and Adjuvant Radiation Therapy in Breast Cancer. Adv Radiat Oncol 9(3):101403, 2024. e-Pub 2024. PMID: 38495037.
      27. Guhan M, Crane SM, Valerius LS, Cruz D, Smith BD, Woodward WA, Mitchell MP, Valero V, Rauch GM, Krishnamurthy S, Warnecke CL, Kuerer HM, Shaitelman SF. Patient interest in exploring non-surgical treatment approaches for early stage breast cancer: A qualitative study. Int J Radiat Oncol Biol Phys 118(2):443-454, 2024. e-Pub 2024. PMID: 37802228.
      28. Sun SX, Piotrowski MJ, Adesoye T, Mitchell MP, Garber HR, Teshome M, Kuerer HM, Tamirisa N, Singh P. Long-Term Outcomes and Predictors of Response in Breast Cancer Patients with Advanced Nodal Involvement. J Am Coll Surg 238(1):1-9, 2024. e-Pub 2024. PMID: 37870227.
      29. Hassan AM, Asaad M, Morris N, Kumar S, Liu J, Mitchell MP, Shuck JW, Clemens MW, Butler CE, Selber JC. Subpectoral Implant Placement is not Protective Against Postmastectomy Radiotherapy-Related Complications Compared to Prepectoral Placement. Plast Reconstr Surg 153(1):24-33, 2024. e-Pub 2024. PMID: 37010459.
      30. Asaad M, Yu JZ, Tran JP, Liu J, O'Grady B, Clemens MW, Largo RD, Mericli AF, Schaverien M, Shuck J, Mitchell MP, Butler CE, Selber JC. Surgical and Patient-Reported Outcomes of 694 Two-Stage Prepectoral vs. Subpectoral Breast Reconstructions. Plast Reconstr Surg 152(4S):43S-54S, 2023. e-Pub 2023. PMID: 36877743.
      31. Baroudi H, Huy Minh Nguyen CI, Maroongroge S, Smith BD, Niedzielski JS, Shaitelman SF, Melancon A, Shete S, Whitaker TJ, Mitchell MP, Yvonne Arzu I, Duryea J, Hernandez S, El Basha D, Mumme R, Netherton T, Hoffman K, Court L. Automated contouring and statistical process control for plan quality in a breast clinical trial. Phys Imaging Radiat Oncol 28:100486, 2023. e-Pub 2023. PMID: 37712064.
      32. Johnson HM, Lin H, Shen Y, Diego EJ, Krishnamurthy S, Yang WT, Smith BD, Valero V, Lucci A, Sun SX, Shaitelman SF, Mitchell MP, Boughey JC, White RL, Rauch GM, Kuerer HM, Study Group ER. Patient-Reported Outcomes of Omission of Breast Surgery Following Neoadjuvant Systemic Therapy: A Nonrandomized Clinical Trial. JAMA Netw Open 6(9):e2333933, 2023. e-Pub 2023. PMID: 37707811.
      33. Gandhi A, Xu T, DeSnyder SM, Smith GL, Lin R, Barcenas CH, Stauder MC, Hoffman KE, Strom EA, Ferguson S, Smith BD, Woodward WA, Perkins GH, Mitchell MP, Garner D, Goodman CR, Aldrich M, Travis M, Lilly S, Bedrosian I, Shaitelman SF. Prospective, early longitudinal assessment of lymphedema-related quality of life among patients with locally advanced breast cancer: The foundation for building a patient-centered screening program. Breast 68:205-215, 2023. e-Pub 2023. PMID: 36863241.
      34. Woodward WA, Mitchell MP. The Elusive Prize of Radiation Therapy Predictive Assays in Breast Cancer. Int J Radiat Oncol Biol Phys 115(1):103-105, 2023. e-Pub 2023. PMID: 36526377.
      35. Kuerer HM, Smith BD, Krishnamurthy S, Yang WT, Valero V, Shen Y, Lin H, Lucci A, Boughey JC, White RL, Diego EJ, Rauch GM, Trials Group ERC. Eliminating breast surgery for invasive breast cancer in exceptional responders to neoadjuvant systemic therapy: a multicentre, single-arm, phase 2 trial. The Lancet 23(12):1517-1524, 2022. e-Pub 2022.
      36. Mitchell MP. Stage IV or Locally Advanced Disease?. Int J Radiat Oncol Biol Phys 114(4):575, 2022. e-Pub 2022. PMID: 36244392.
      37. Mitchell MP. High Reward and Low Risk. Int J Radiat Oncol Biol Phys 114(2):183, 2022. e-Pub 2022. PMID: 36055316.
      38. Aldrich MB, Rasmussen JC, DeSnyder SM, Woodward WA, Chan W, Sevick-Muraca EM, Mittendorf EA, Smith BD, Stauder MC, Strom EA, Perkins GH, Hoffman KE, Mitchell MP, Barcenas CH, Isales LE, Shaitelman SF. Prediction of breast cancer-related lymphedema by dermal backflow detected with near-infrared fluorescence lymphatic imaging. Breast Cancer Res Treat 195(1):33-41, 2022. e-Pub 2022. PMID: 35816269.
      39. Diao K, Andring LM, Barcenas CH, Singh P, Carisa Le-Petross H, Reed VK, Reddy JP, Bloom ES, Ahmad NR, Mayo LL, Perkins GH, Mitchell MP, Nead KT, Tereffe W, Smith BD, Woodward WA. Contemporary Outcomes After Multimodality Therapy in Patients With Breast Cancer Presenting With Ipsilateral Supraclavicular Node Involvement. Int J Radiat Oncol Biol Phys 112(1):66-74, 2022. e-Pub 2022. PMID: 34710521.
      40. O'Sullivan CC, Ballman KV, McCall L, Kommalapati A, Zemla T, Weiss A, Mitchell M, Blinder V, Tung NM, Irvin WJ, Lee M, Goetz MP, Symmans WF, Borges VF, Krop I, Carey LA, Partridge AH. Alliance A011801 (compassHER2 RD): postneoadjuvant T-DM1 + tucatinib/placebo in patients with residual HER2-positive invasive breast cancer. Future Oncol. e-Pub 2021. PMID: 34636255.
      41. Nia ES, Huang ML, Sun SX, Mitchell MP, Myatt JP, Candelaria RP. The mammographic appearance of the BioMonitor implantable loop recorder. Clin Imaging 73:28-30, 2021. e-Pub 2021. PMID: 33296770.
      42. Mamounas EP, Mitchell MP, Woodward WA. Molecular Predictive and Prognostic Markers in Locoregional Management. J Clin Oncol 38(20):JCO1902905, 2020. e-Pub 2020. PMID: 32442060.
      43. Li XA, Moughan J, White JR, Freedman GM, Arthur DW, Galvin J, Xiao Y, McNulty S, Lyons JA, Kavadi VS, Fields MT, Mitchell MP, Anderson BM, Lock MI, Kokeny KE, Bazan JG, Currey AD, Hijal T, Cheston SB, Vicini FA. Patterns of failure observed in the two-step institution credentialing process for NRG Oncology/RTOG 1005 (NCT01349322) and lessons learned. Pract Radiat Oncol 10(4):265-273, 2020. e-Pub 2020. PMID: 31790823.
      44. Myers JS, Mitchell M, Krigel S, Steinhoff A, Boyce-White A, Van Goethem K, Valla M, Dai J, He J, Liu W, Sereika SM, Bender CM. Qigong intervention for breast cancer survivors with complaints of decreased cognitive function. Support Care Cancer 27(4):1395-1403, 2019. e-Pub 2019. PMID: 30128855.
      45. Butler-Xu YS, Marietta M, Zahra A, TenNapel M, Mitchell M. The effect of breast volume on toxicity using hypofractionated regimens for early stage breast cancer for patients. Adv Radiat Oncol 4(2):261-267, 2019. e-Pub 2019. PMID: 31011671.
      46. Myers JS, Kahya M, Mitchell M, Dai J, He J, Moon S, Hamilton K, Valla M, O'Dea A, Klemp J, Kurylo M, Akinwuntan A, Devos H. Pupillary response: cognitive effort for breast cancer survivors. Support Care Cancer 27(3):1121-1128, 2019. e-Pub 2019. PMID: 30097791.
      47. Ganju RG, Savvides G, Korentager S, Ward MJ, TenNapel M, Amin A, Wagner J, Mitchell M. Incidence of breast lymphedema and predictors of its development in patients receiving whole breast radiation therapy after breast-conservation surgery. Lymphology(52):126-133, 2019. e-Pub 2019. PMID: 31874124.
      48. Kilgore LJ, Korentager SS, Hangge AN, Amin AL, Balanoff CR, Larson KE, Mitchell MP, Chen JG, Burgen E, Khan QJ, O'Dea AP, Nye L, Sharma P, Wagner JL. Reducing Breast Cancer-Related Lymphedema (BCRL) Through Prospective Surveillance Monitoring Using Bioimpedance Spectroscopy (BIS) and Patient Directed Self-Interventions. Ann Surg Oncol 25(10):2948-2952, 2018. e-Pub 2018. PMID: 29987599.
      49. Mitchell MP, Wagner J, Butterworth J. Subcutaneous implant-based breast reconstruction, a modern challenge in postmastectomy radiation planning. Pract Radiat Oncol 8(3):153-156, 2018. e-Pub 2018. PMID: 29233522.
      50. Mallory ML, Mitchell MP. Lymphangioleiomyomatosis: A new relative contraindication for breast conservation therapy. Adv Radiat Oncol 3(1):16-18, 2018. e-Pub 2018. PMID: 29556574.
      51. Arguello AA, Richardson BD, Hall JL, Wang R, Hodges MA, Mitchell MP, Stuber GD, Rossi DJ, Fuchs RA. Role of a Lateral Orbital Frontal Cortex-Basolateral Amygdala Circuit in Cue-Induced Cocaine-Seeking Behavior. Neuropsychopharmacology 42(3):727-735, 2017. e-Pub 2017. PMID: 27534268.
      52. Stecklein SR, Shen X, Mitchell MP. Post-Mastectomy Radiation Therapy for Invasive Lobular Carcinoma: A Comparative Utilization and Outcomes Study. Clin Breast Cancer 16(4):319-26, 2016. e-Pub 2016. PMID: 26943990.
      53. Reddy JP, Dawood S, Mitchell M, Debeb BG, Bloom E, Gonzalez-Angulo AM, Sulman EP, Buchholz TA, Woodward WA. Antiepileptic drug use improves overall survival in breast cancer patients with brain metastases in the setting of whole brain radiotherapy. Radiother Oncol 117(2):308-14, 2015. e-Pub 2015. PMID: 26482599.
      54. Mitchell MP, Abboud M, Eng C, Beddar AS, Krishnan S, Delclos ME, Crane CH, Das P. Intensity-modulated radiation therapy with concurrent chemotherapy for anal cancer: outcomes and toxicity. Am J Clin Oncol 37(5):461-6, 2014. e-Pub 2014. PMID: 23466576.
      55. Lang JE, Tereffe W, Mitchell MP, Rao R, Feng L, Meric-Bernstam F, Bedrosian I, Kuerer HM, Hunt KK, Hortobagyi GN, Babiera GV. Primary tumor extirpation in breast cancer patients who present with stage IV disease is associated with improved survival. Ann Surg Oncol 20(6):1893-9, 2013. e-Pub 2013. PMID: 23306905.

      Review Articles

      1. Doke K, Butler S, Mitchell MP. Current Therapeutic Approaches to DCIS. J Mammary Gland Biol Neoplasia 23(4):279-291, 2018. e-Pub 2018. PMID: 30267199.
      2. Mitchell MP, Sharma P. The Use of Surgery and Radiotherapy as Treatment of Regional Nodes in Breast Cancer Patients. Oncology (Williston Park) 32(6):e52-e64, 2018. e-Pub 2018. PMID: 29940065.

      Professional Educational Materials

      1. . ACR Radiation Oncology In-Training, 2021.

      Other Articles

      1. Mitchell MP Cardiovascular Health Across the Life Course for Individuals with Breast Cancer. JAMA Cardiology.
      2. Shah, C, Mitchell, MP Proton Therapy for Breast Cancer—Is the Door Shut?. JAMA Network Open 9(1), 2026. PMID: 41569569.

      Abstracts

      1. Liu YF, Singh P, Moulder S, Woodward W, Shaitelman S, Perkins G, Lucci A, Middleton L, Smith B, Mitchell MP. Impact of Surgery Type and Radiation Fractionation on Outcomes in Node-Negative Metaplastic Breast Cancer 44(10):S41-S41, 2021.
      2. Kuerer H, Smith B, Valero V, Krishnamurthy S, Diego E, Yang W, Shen Y, Lucci A, Lin H, Johnson H, Moseley T, Boughey JC, Shaitelman S, White R, Mitchell M, Teshome M, Miggins M, Hunt KK, Rauch GM. Eliminating breast surgery for invasive cancer after neoadjuvant systemic therapy: 5-year outcomes on an inaugural multicenter phase 2 clinical trial. Meeting of the Society-of-Surgical-Oncology 32(S1):S28-S28.
      3. Mitchell MP, Abboud M, Crane CH, Eng C, Chang CJ, Rodriguez-Bigas MA, Skibber JM, You YN, Beddar S, Krishnan S, Delclos M, Das P. Intensity-modulated radiation therapy (IMRT) with concurrent chemotherapy for anal cancer: A large single-institution experience. Gastrointestinal Cancers Symposium of the American-Society-of-Clinical-Oncology 30(4S).
      4. O'Sullivan CCM, Ballman KV, McCall LM, Zemla TJ, Weiss A, Mitchell M, Blinder VS, Tung NM, Irvin WJ, Lee M, Goetz MP, Symmans WF, Borges VF, Krop IE, Partridge AH, Cary LA. Postneoadjuvant T-DM1+tucatinib/placebo in patients with residual HER2-positive. Virtual Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) 39(15S).
      5. Morse R, Moreno M, Butterworth J, Mitchell MP. Interplay of Oncoplastic Reconstruction and Radiation Therapy with Associated Patient Reported Outcomes 45(9):S25-S25.
      6. Johnson HM, Diego EJ, Krishnamurthy S, Yang W, Smith B, Valero V, Lucci A, Shaitelman S, Mitchell M, Boughey JC, White R, Rauch G, Kuerer H. Multicenter Clinical Trial for Omission of Breast Surgery on Invasive Cancer Following Neoadjuvant Systemic Therapy: Longitudinal Patient Reported Outcomes and Decisional Comfort Planned Analyses. Annual International Conference of the Society-of-Surgical-Oncology (SSO) on Surgical Cancer Care 30(SUPPL1):S11-S12.
      7. Goodman CR, Shaitelman S, Hoffman K, Mitchell MP, Strauss JB, Ramezani S, Zia A, Comeaux N, Virk R, Lin RT, Nead K, Stauder MC, Strom E, Perkins G, Bloom E, Reed V, Joyner M, Schlembach P, Lim B, Barcenas C, Smith BD, Lucci A, Woodward WA. Dynamics of Circulating Tumor Cell Response with Adjuvant or Pre-Operative Radiotherapy in Locally Advanced Breast Cancer: A Prospective Cohort Study 206(S1):S639-S640.

      Book Chapters

      1. Moscol G, Hwang R, Mitchell M. Breast Cancer. In: Gynecologic Care of the Female Cancer Patient, 2023.
      2. Amin A, Mitchell M. Axillary surgery vs Radiation as treatment of regional nodes: AMAROS trial and beyond. In: Spear's Surgery of the Breast: Principles and Art. 4e edited by Allen Gabriel, 2020, 2020.
      Read More
      Less

      Patient Reviews


      CV information above last modified August 03, 2026

      Request an Appointment

      Whether you are ready to make an appointment now or have questions for our expert team, we are standing by to help.
      Learn more

      Related Links

      • Care Centers and Clinics

      • Departments and Divisions

      • Labs

      Clinical Trials

      Our patients have access to clinical trials offering promising new treatments that cannot be found anywhere else.
      Learn more

      Help #EndCancer

      Give Now

      Your gift will help make a tremendous difference.
      Donate

      Donate Blood

      Our patients depend on blood and platelet donations.

      Make an appointment

      Shop UT MD Anderson

      Show your support for our mission through branded merchandise.

      View products
      Subscribe to our Cancerwise newsletter
      UT MD Anderson logoUT MD Anderson logo
      • Explore
      • Patients & Family
      • Prevention & Screening
      • Donors & Volunteers
      • For Physicians
      • Research
      • Education & Training
      • Clinical Trials
      • Languages
      • About
      • About UT MD Anderson
      • Careers
      • Blog
      • Newsroom
      • Editorial Standards
      • For Employees
      • Merchandise
      • Title IX Reporting (Sexual Misconduct)
      • Price Transparency
      • Finding Your Way
      • Our Doctors
      • Locations
      • Directions
      • Sitemap
      • DIGITAL ACCESSIBILITY
      • Accessibility Policy MD Anderson works with Level Access to ensure our website is accessible and functional for all users. Free assistive technology is provided for people with physical disabilities. To learn more or to download the assistive technology tool, visit https://www.levelaccess.com/MDAnderson
      • GET IN TOUCH
      • Call
        1-877-632-6789
      • Ask a question
      • Stay Connected
      • Cancerwise Podcast
      • More
      • Website Privacy Policy
      • Legal Statement & Policies
      • Reports to the State
      • Emergency Alert Information
      • State of Texas Links
      • Our Cancer Network
      • Vendors & Suppliers
      UT MD Anderson logo
      The mission of The University of Texas MD Anderson Cancer Center is to eliminate cancer in Texas, the nation, and the world through outstanding programs that integrate patient care, research and prevention, and through education for undergraduate and graduate students, trainees, professionals, employees and the public.

      © 2026 The University of Texas MD Anderson Cancer Center. All rights reserved.

      Top